Market Volatility Increases After PPI Data; S&P 500 Settles Higher

U.S. stocks extended gains on Thursday, with the Nasdaq gaining over 1% for a second session in a row.

U.S. stocks extended gains on Thursday, with the Nasdaq gaining over 1% for a second session in a row.

Producer prices for final demand in the U.S. rose 0.1% month-over-month in June, compared to market expectations of a 0.2% increase. U.S. initial jobless claims, meanwhile, declined by 12,000 from the previous week to 237,000 in the week ending July 8, compared to market estimates of 250,000.

Big banks, including JPMorgan Chase & Co. (NYSE:JPM), Citigroup Inc. (NYSE:C) and Wells Fargo & Company (NYSE:WFC) will release earnings on Friday.

PepsiCo, Inc. (NASDAQ:PEP) shares gained 2.4% on Thursday after the company increased its annual revenue and profit guidance.

Majority of sectors on the S&P 500 closed on a positive note, with communication services and information technology stocks recording the biggest gains on Thursday. However, energy and health care stocks closed lower during the Thursday’s session.

The Nasdaq 100 rose 1.73% to close at 15,571.98 on Thursday, amid gains in shares of Amazon.com, Inc. (NASDAQ:AMZN) and Alphabet Inc. (NASDAQ:GOOGL).

The S&P 500 rose 0.85%, while the Dow Jones gained 0.14% to 34,395.14 in the previous session.

The Chicago Board Options Exchange’s CBOE Volatility Index (VIX) rose 0.5% to close at 13.61 on Thursday.

What is CBOE Volatility Index?

The CBOE Volatility Index, popularly known as VIX, is a measure of the equity market’s expectation of volatility based on S&P 500 index call and put options.

 

Read Next: JPMorgan Likely To Report Higher Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF